Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — New Poll Finds Majority of Americans Support Drug Decriminalization

A recent poll conducted by the Drug Policy Alliance (“DPA”) and the American Civil Liberties Union (“ACLU”) has found that more than half of the voters in America are in favor of the drug war coming to an end and also support the decriminalization of the simple possession of substances which are presently illegal.

The poll was conducted last month and interviewed 800 registered voters. Its results were released just before the 50th anniversary of the declaration of the drug war by former president Richard Nixon, which began a system of mass criminalization, which disproportionately targeted individuals of color. Of those surveyed, more than 60% were found to support the elimination of criminal penalties for drug possession and reinvesting resources used for drug enforcement into addiction and treatment services. Another 65% agreed that the United States should withdraw from the drug war.

Surprisingly, the survey also found that a considerably large number of voters felt that the war on drugs had failed. By party affiliation, 82% of members of the GOP, 85% of independents and 83% of Democrats regarded the war on drugs as a failure.

In a press release, the ACLU Justice Division’s director Udi Ofer stated that President Joe Biden should move to dismantle the system of mass incarceration and overpolicing as per his campaign promises, on the anniversary of the war on drugs. In addition to this, the poll also found that more than 60% of those surveyed believed that the use of drugs shouldn’t be treated as a criminal justice issue and should instead be viewed as a public health issue, while another 61% supported the commuting of sentences for drug-related convictions. An additional 64% supported the revocation of mandatory minimum sentences in cases related to drugs.

Ofer asserted that the time had come to embrace new approaches that treated substance use as a public health issue. He noted that the Biden administration could make progress in ending this racist and harmful war by reducing the sentences of individuals imprisoned for drugs. This, he said, would help decrease the over policing of Brown and Black communities in the United States, as well as decrease the problem of mass incarceration.

President Biden has vocalized his support for ending imprisonment for low-level drug cases, stating that no individual should be incarcerated for using drugs. He added that the country should change the way they dealt with drug abuse. However, the Biden administration has yet to take any steps to alter federal policy. Additionally, the president hasn’t granted presidential clemency to individuals imprisoned for drugs.

Should federal marijuana policy ever be relaxed, industry players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) will have fewer regulatory headaches to contend with as a degree of uniformity may be brought to the currently fractured industry.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces Expanded East Coast Capacity to Meet Surging Demand

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER),the country’s largest independent alkaline water company, today announced that two of its leading suppliers have expanded their capacity by opening east coast facilities. According to the update, the company’s exclusive arrangements with these manufacturers will alleviate raw material concerns during its east coast expansion. Additionally, to meet anticipated demand, the company intends to add three new strategically located co-packers prior to the end of the third quarter. “As we position ourselves for continued growth, we continue to deploy assets that allow our production to exceed increased demand for Alkaline88(R),” said Ricky Wright, president and CEO of The Alkaline Water Company. “While much of the industry finds itself squeezed with raw material demands and capacity constraints, we’ve never been stronger. Our foresight to find multiple domestic sources for our raw materials paid dividends last year. Over the last six months, two of our west coast providers have opened operating facilities on the east coast.”

To view the full press release, visit https://cnw.fm/BVjlE

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products Inc. includes the company’s lab-tested, hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules, and gummies. To learn more about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — NFL Funds Cannabis Research Despite Continued Prohibition Hindering Research

The NFL-NFLPA Committee, which was formed by the players’ union in the National Football League and the NFL, recently revealed its plans to award grants to researchers to facilitate research on the therapeutic potential of CBD, cannabis and other opioid alternatives for pain management.

During a press conference held last week, a representative from the Joint Pain Management Committee stated that there were numerous innovative ideas in the psychedelics space, adding that important research needed to be financed.

Dr. Kevin Hill, co-chair of the committee, stated that the federal policy unfavorably affected the level of research permitted, given the ongoing prohibition of marijuana, which is still categorized as a Schedule I drug. Hill also noted that lack of financing in this field of research also affected advancements in research. He explained that many companies and states that were profiting significantly through the sale of marijuana as well as other cannabinoids weren’t contributing to science.

This funding opportunity aims at requesting proposals from researchers who have the ability to conduct studies that can supplement the committee’s knowledge on athletic performance and pain management in football players. In particular, the league would like proposals on the following areas of inquiry:

The effects of cannabinoids or marijuana on athletic performance in football players, e.g., in reaction time, cardiorespiratory or psychomotor function
The effects of nonpharmacologic treatments on pain in football players, be it everyday pain management or postsurgical pain management
The effects of cannabinoids on pain in football players

A notice released by the NFL states that the deadline for applications to be submitted prior to proposals is July 31, 2021.

In 2020, the joint panel held CBD informational forums, which led to the determination that the marijuana compound, which is nonintoxicating, shows potential in the treatment of various forms of pain. However, the committee felt there was not enough information and research existed on the benefits of opioid alternatives for both chronic and acute pain.

The NFL policy also highlights that players in the league won’t face suspension from games based on positive tests for any substance, including cannabis. This policy, which was recently revised, reflects a considerable shift in the NFL’s approach to the use of drugs by players, with the agreement highlighting the need to center on treatment and evaluation rather than penalties.

Players who self-refer themselves, display behaviors that indicate misuse of drugs or test positive for drug use are now required to enroll in an intervention program, where they can be evaluated and receive a treatment plan.

As more becomes known about the therapeutic potential of marijuana and its compounds, the dose-measuring devices made by companies such as RYAH Group Inc. (CSE: RYAH) are likely to see an upsurge in demand.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Extractors Keep Microbials, Mold from Cannabis Products

The cannabis industry has been riding high for the past few years, earning billions of dollars as more states have chosen to legalize it for either medical or recreational use — even both. Despite cannabis becoming even more accessible, many consumers don’t stop to think about how much care is taken to ensure the products they see on the shelves are of top quality.

Anyone who deals with plant material early on in the supply chain will tell you moisture is enemy number one. With moisture comes mold and microbials, and when it comes to marijuana and hemp extracts, handling and storing the raw plant material improperly leaves it vulnerable to mold and microbials that can — and will — spoil the entire batch.

So how do extractors keep these two away during the extraction process? Well, for starters, they make sure raw plant material is properly tested and stored before the extraction process, and they work hard to keep moisture out during all extraction stages. Additionally, they can employ the solvent-based processes used during extraction to eliminate contaminants, and once extraction is complete, they store the finished products in air-tight containers.

According to Andras Gaspar, chief product officer at chromatography technology company RotaChrom Technologies, microbials will both degrade plant material and secrete toxins. The raw plant material will not only be earmarked for disposal, but it can also be deemed hazardous waste. To prevent this from happening, extractors use extraction processes that some have dubbed “kill steps” to get rid of contamination from the plants.

Irradiation will eliminate contaminants even before the plant is processed. It does not degrade CBD, THC or terpene content, says Quinn Shiskin, director of products and innovation at British Columbia-based cannabis product manufacturer the Valens Co. Depending on the solvent used during the extraction process, the plant material can be cleansed again, with solvents such as ethanol being great at removing microbials and mold.

Winterization, which sees the extracted solvent chilled to extremely low temperatures (-80 degrees Celsius) for up to 48 hours to get rid of impurities such as wax, is also a kill step. The crude oil is then superheated to create a distillate, providing another kill step that further cleanses it of contaminants. Craig Henderson, CEO of Boulder, Colorado-based CBD producer Extract Labs, says eliminating moisture is the best way to keep microbials and mold at bay.

His company uses hydrocarbon and CO2 for solvent extraction, then superheats the crude oil and employs alcohol during the winterization process to get rid of moisture and kill contaminants. A rotary evaporator is used to remove any remaining moisture. On top of that, his team cleans all work surfaces with isopropyl alcohol, keeping the packaging and labeling zones separate, and packs the finished products in sealed jars in dark, temperature-controlled environments.

Needless to say, the most reputable cannabis extraction companies, including BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), go an extra mile of subjecting their products to stringent third-party tests so that product buyers can be sure that no contaminant is present in what they are going to consume.

NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Why American Cannabis Partners Is ‘One to Watch’

American Cannabis Partners (“ACP”) is a multistate cannabis company with a retail license and 560,000 square feet of licensed canopy space for cultivation. ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on federal interstate commerce opportunities. As a company that is focused on complementary business segments — real estate, acquisition and development of proprietary assets and ongoing cultivation operations, ACP is targeting expansion. A recent article reads, “American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri, and Massachusetts.”

To view the full article, visit https://cnw.fm/5FJtU

About American Cannabis Partners

American Cannabis Partners is a fully licensed, large scale and 100% organic cannabis cultivation company nationally headquartered in Trinity County of the Emerald Triangle. As business professionals and cultivators, the company focuses on four industry segments: real estate, cultivation, medical research, and non-profit groups. For both medical and recreational, American Cannabis Partners supplies multiple forms of raw product at wholesale prices for manufacturing, distribution and retail licenses. Its commodity pricing model enables stable profit margins for customers, and the company has expanded into multiple states. For more information, visit www.ACPFarms.com.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks — Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Names New Auditor, Provides Filing Update

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has released an update regarding its annual filing statements for FY 2020, the period ended Dec. 31, 2020. The update also applies to other related documents, including the CEO and CFO certificates, an annual information form, and management’s discussion and analysis. RWB announced that it is now working with Macias Gini & O’Connell LLP (“MGO”) as the successor auditor to replace MNP LLP (“MNP”), the company RWB had previously contracted with. In addition, Red White & Bloom Brands noted that it will be filing its change of auditor package concurrently with the securities commissions to reflect the appointment of MGO as its auditor. RWB announced last month that there would be a delay in filing its documents because its auditor at the time, MNP, had not completed required audit procedures in time. The company reiterated that it is working diligently to finalize and file its documents and will continue to release biweekly default status reports until the documents are filed.

To view the full press release, visit https://cnw.fm/yzlMK

About Red White & Bloom Brands Inc.

Red White & Bloom Brands is positioning itself to be one of the top-three, multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California, with respect to cannabis, as well as the United States and internationally for hemp-based CBD products. For more information about the company, please visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Congressional Bill Could Enable Researchers to Study Cannabis from Dispensaries

Earlier this week, a congressional committee revealed its plans to vote on a legislation that will enable scientists to study cannabis products from state-legal dispensaries. The 1,200-page legislation, which has been advanced to the House Transportation and Infrastructure Committee, will allow researchers to carry out research on impaired driving using actual cannabis products that consumers use and purchase. Additionally, it would enable the interstate distribution of marijuana to researchers in jurisdictions that are yet to legalize the plant.

This isn’t the first time the bill has been introduced, as an earlier version that had similar cannabis provisions was passed in the House last Congress. However, that measure wasn’t approved in the Senate, which was GOP-controlled.

The current bill, which was sponsored by Peter DeFazio who is chair of the House Transportation Committee, also contains a provision that would compel states where cannabis is legal to consider educating people about and discourage them from driving while under the influence of marijuana.

However, advocates disagree with the language used in the provision, as it targets jurisdictions where cannabis is legal while ignoring the fact that cannabis-impaired driving occurs whether or not the herb is legal. Those advocates are, however, encouraged by the clause that calls on the Department of Transportation to work with the Department of Health and Human Services and the Attorney General to create a report that has recommendations on offering scientists access to strains and samples of cannabis and products that contain cannabis lawfully being provided to consumers or patients in legal states.

The clause notes that the report should also look into establishing a clearing house to gather and distribute strains and samples of cannabis for scientific research, which would include marijuana from state-legal markets. In addition to this, the legislation notes that the report should also examine regulatory and statutory barriers that would hinder scientific research from being conducted.

The measure also calls for the amendment of present law to include a section stipulating that states with legalized recreational and medical cannabis legislation shall consider adding programs to decrease deaths and injuries that occur as a result of cannabis-impaired driving as well as educate drivers on the risks linked to cannabis-impaired driving. However, some advocates have disagreed with the implication that legalizing marijuana increases the risk of individuals driving while impaired.

If this bill is enacted, it could potentially remove some of the hurdles that companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) face in their efforts to develop cannabis-based medicinal formulations.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — AI Could Help Despite Shortage of Cannabis Data

Even though cannabis has been legal for either medical or recreational use in several states for years now, its status as a classified drug at the federal level has been a constant thorn in the state-legal cannabis industry’s side. Not only has this made navigating the business and financial world extremely challenging for cannabis businesses, but it has made any sort of research into cannabis nearly impossible.

With the young cannabis sector growing bigger every year, the lack of scientific data on marijuana poses a major problem, especially in regards to medical cannabis.

Cannabis produces more than 100 compounds called cannabinoids, but most of the existing data focuses on THC and CBD, the most abundant cannabinoids. Although most of the other cannabinoids are present in minute levels, they interact with each other in a phenomenon dubbed the “entourage effect,” affecting how each strain affects people. However, we have barely any data on these other substances of the entourage effect.

Cannabis may still be illegal at the federal level, but stakeholders and medical cannabis patients need this data now. As such, researchers from the University of Colorado Boulder cast their nets out for ways they could find reliable data on how the cannabis plant works. Their study, which was recently published in the journal “Plos One,” suggests that artificial intelligence (“AI”) could help fill the massive knowledge gap plaguing the nascent cannabis industry.

Diana Vergara, an evolutionary biologist at CU Boulder, says that although the industry treats cannabis varieties as if they were standardized, much like Girl Scout Cookies or Gorilla Glue, in actuality the smell, taste and overall effects are never standard. On top of minor cannabinoids, a wide variety of flavonoids and terpenes also impact the taste, aroma and overall effect of a cannabis plant. To get a full analysis of all the chemicals in the cannabis plant, Vergara teamed up with Brian Keagan, an assistant professor in CU Boulder’s Department of Information Science to analyze data from more than 17,600 cannabis flower cultivars.

Most of this data focused on THC and CBD, with only 153 samples containing data on the other seven main cannabinoids. Data on the minor cannabinoids was barely present, with some of them not even being measured. To figure out this missing data, the team employed machine learning, using statistical methods and algorithms to find hidden patterns in the data sets. They found that the assumption that strains with more THC have less CBD, and vice versa, was false, and that strain names are not reliable indicators of the chemical makeup or overall potency.

This is just a start, the researchers note, saying they need widespread industry cooperation if they are to use this technology to fill the sector’s knowledge gaps. Data from more cultivars, however insufficient it is, will help the researchers use AI technology to figure out chemical interactions and how they can be harnessed for human benefit. Among other things, retailers would be able to list full chemical profiles on product labels, and it would lead to a much more reliable strain-naming system.

Cannabis companies such as Hero Technologies Inc. (OTC: HENC), which are looking to genetically engineer cannabis cultivars, could massively benefit from the deployment of AI in their operations.

NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Marijuana Extracts: The New Focus of the Marijuana Industry

As the global marijuana industry continues growing, major businesses are partnering with companies in the industry, conducting research and exploring marijuana in an attempt to develop new product lines for the medical and recreational segments of the industry.

In addition, regulatory changes are being made through supportive federal legislative action in the marijuana space allowing marijuana extraction companies to grab innovative economic investment opportunities as well as develop a new generation of edibles.

Estimates show that by 2026, the global marijuana industry will reach $97 billion, with a compounded annual growth rate of roughly 32% in that period. However, while marijuana and its byproducts are utilized in various medical and recreational capacities, preliminary sector growth has shown that more profits will be made via products that need specialized techniques and additional processing to manufacture, such as beverages, oils and edibles.

This explains why a number of companies are focused on marijuana extracts and the production of new edible products.

So, what are marijuana extracts?

Marijuana extracts refer to different products that contain higher levels of CBD and THC than are commonly found in the marijuana plant. The CBD and THC levels of marijuana extracts can vary significantly, with some extracts hitting 99% high CBD or THC.

CBD, or cannabidiol in full, is a popular cannabinoid that is commonly seen as a therapeutic solution for mental issues and pain, among other problems. The anecdotal evidence notwithstanding, more research is required to confirm the nonintoxicating cannabinoid’s possible medical uses and benefits.

On the other hand, tetrahydrocannabinol, or THC for short, is a cannabinoid that induces a high and offers its users an intoxicating and euphoric experience.

So, how will extracts benefit the marijuana industry?

A BDS Analytics and ArcView Market Research report released in 2018 forecasted that the marijuana edibles market in North America would be more than $4 billion by 2022, noting that drink and food products made up nearly 12% of total marijuana spending in 2017, in both the United States and Canada.

This information has prompted many extraction companies to diversify their avenues of revenue and portfolio of services to enhance their value. Other companies have developed more vertically integrated business models to grow their autonomy in the marijuana market as well as manage their exposure in the growing space.

Formulation engineering and technological advancement has created progressive tools to alter marijuana at the molecular level for greater bioavailability, which will enable extraction providers and manufacturers of edibles to boost consumer trust.

Some companies, such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), have already established themselves in the cannabis extracts niche, and they are well ahead of any others that are looking to join this promising segment.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Federally Funded Research Concludes Testing THC Level to Detect Driver Impairment Is Unreliable

In a bid to reduce the rates of impaired driving as cannabis becomes more accessible, several states have set THC thresholds that bar individuals who have more than a certain amount of THC in their system from driving. The thinking is that, as with alcohol, higher levels of THC in the blood are directly responsible for higher levels of impairment, and establishing a threshold gives law enforcement officials a standard for which they can test to see how impaired an individual is. While it is a noble policy that’s geared towards ensuring safety on the roads, cannabis proponents have long argued that such THC limits are arbitrary and have no scientific backing.

A study funded by the National Institute of Justice (“NIJ”) sought to find the relationship between THC levels and impairment, and the results were quite interesting. After giving basic field sobriety and cognitive tests to 20 individuals who had consumed cannabis, either as edibles or as vapes, the federally funded study found that the amount of THC in an individual’s system could not be used to accurately predict impairment. It’s not in question that consuming cannabis with moderate to high levels of THC will impair your thinking and physical reactions.

Study participants who consumed more than 5mg of THC all experienced observable psychomotor impairment, the RTI International researchers found. However, they concluded that THC levels were not an accurate and reliable indicator of cannabis intoxication in the test participants, regardless of the mode of consumption used orally, smoked or vaped.

Although this is just one study with a limited number of participants, the results provide some evidence in support of what many cannabis proponents have been saying: per se laws limiting THC levels and barring people from driving may not be fully based on scientific evidence.

Paul Armentano, NORML deputy director, isn’t surprised by the study’s findings, saying there is no science backing the per se THC threshold policies being enforced by several states. Additionally, the tests used to determine impairment did not seem to work on any of the study participants, with tests such as standing on one leg, balancing and walking in a straight line being poor indicators of cannabis impairment.

In some cases, the levels of THC, cannabidiol and cannabinol reported by the toxicology tests did not correlate with the observable cognitive and psychomotor impairment. Some study subjects would be highly impaired while tests showed their systems had low THC levels, yet the per se laws in some states would allow these individuals to stay on the road. As such, the researchers concluded that while THC does cause impairment, THC levels in the blood, urine and saliva are not reliable indicators of cannabis intoxication.

These findings from a federally funded study address one of the misconceptions regarding cannabis that the entire industry, including Sonoma Biologics Corp., have encountered at one point or another. Hopefully, more information will become available on how to accurately determine cannabis intoxication among motorists.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.